Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

GLP-2

Repair & Recovery

Molecular Dossier

  • Rank Index: 60
  • Status: FDA Approved (Orphan)
  • What does this mean?
  • Molecular Structure: MW: 3752.2 Da | 33 AA sequence | Half-life: ~7 hrs (Teduglutide vs. 7 min native)

About GLP-2

Glucagon-like peptide-2 is an endogenous intestinotrophic hormone secreted by L-cells in response to nutrient intake. Stimulates intestinal epithelial proliferation, reduces gut permeability, and enhances nutrient absorption. Teduglutide (Gattex/Revestive) is an FDA-approved GLP-2 analogue for short bowel syndrome.

Clinical Focus

Intestinal Mucosal Repair, Gut Barrier Integrity, Nutrient Absorption

Archival Aliases

Teduglutide, Gattex, Revestive, Intestinal GLP-2

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight MW: 3752.2 Da | 33 AA sequence | Half-life: ~7 hrs (Teduglutide vs. 7 min native)
Primary Pathway Repair & Recovery
Research Phase FDA Approved (Orphan)

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] pubmed.ncbi.nlm.nih.gov
[REF 2] pubmed.ncbi.nlm.nih.gov

Data Verified: 2026-04-14

Synergistic Matrix